Ascendis Pharma AS (NAS:ASND)
$ 124.33 -2.22 (-1.75%) Market Cap: 7.43 Bil Enterprise Value: 7.88 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Ascendis Pharma A/S at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 03:40PM GMT
Release Date Price: $97.2 (+2.08%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Good morning, everybody. Thanks for joining us for our first day of the Bank of America Healthcare Conference. I am Tazeen Ahmad. I'm one of the senior SMid biotech analysts here at the firm. It is my pleasure to have our next presenting company management with us from Ascendis. We're happy to have several members of the management team sitting right next to me is, of course, the famous Marie Hartoft. Good morning. Thank you for joining us. Also listening up to me is CFO of Scott Smith, and of course, Tim Lee from Investor Relations. So I think Tim is going to read a disclaimer and then we'll go straight to Q&A.

Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Thank you. We may make forward-looking comments during this presentation, including statements regarding our projections for SKYTROFA revenue in 2023, our plans regarding TransCon PTH and our other product candidates, our cost control measures and productivity

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot